A randomised phase II trial of dexamethasone and aspirin (DA) versus dexamethasone, diethylstilboestrol and aspirin (DAS) in locally advanced or metastatic cancer of the prostate

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13255144

Enrollment

260

Registered

2003-09-12

Start date

2001-01-01

Completion date

Unknown

Last updated

2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Cancer Malignant neoplasm of the prostate

Interventions

Randomised phase II clinical trial, 130 in each arm: Group 1: receiving 'DA' which is a combination of dexamethasone, aspirin and ranitidine Group 2: receiving 'DAS' dexamethasone, aspirin, ranitidine

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: North East Thames region (Whipps Cross, Oldchurch, King George, St. Bartholomew's). Patients over the age of 18 years who have locally advanced metastatic prostate specific antigen (PSA)-positive adenocarcinoma after failure of gonadotropin releasing hormone (GnRH) analogue therapy, radiation therapy, surgery or any combination of these.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
1. PSA response rate 2. Quality of life	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026